{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:30Z","timestamp":1792417410513,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Background and Objectives:<\/jats:title>\n Ocrelizumab is an established therapy for multiple sclerosis (MS). However, real-world data from Indian clinical settings remain limited. Hence, the present study was conducted to evaluate the clinical effectiveness, radiological response, and safety profile of ocrelizumab over 12 months of therapy among patients with MS in India.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This retrospective observational study included data from adults diagnosed with multiple sclerosis (MS) who received ocrelizumab for at least 12 months. Clinical, radiological, and safety data were recorded. Primary outcomes were changes in the Expanded Disability Status Scale (EDSS) score and relapse rate. Secondary outcomes included magnetic resonance imaging (MRI) lesion counts and safety events. Statistical comparisons were performed.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Fifty-five patients were included with a mean age of 38.2 (8.75) years. 61.8% were female. EDSS scores improved significantly from 3.77 (1.71) at baseline to 3.28 (2.05) at 12 months (\n P<\/jats:italic>\n < 0.001). The annualized relapse rate decreased from 0.60 to 0.15, and MRI analysis showed significant reductions in both T2 lesions (17.06 [12.94] to 1.09 [2.38];\n P<\/jats:italic>\n < 0.001) and gadolinium-enhancing T1 lesions (1.26 [1.17] to 0.06 [0.23];\n P<\/jats:italic>\n < 0.001). Clinically indicated MS-related hospitalizations (excluding all treatment-administration admissions) decreased from 32.7% before treatment to none during the 12-month follow-up. No serious adverse events were reported, and 96.4% of patients experienced no adverse events. Regression analysis identified baseline EDSS as the only independent predictor of disability at 12 months.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Twelve months of ocrelizumab therapy was associated with significant reductions in relapse activity and MRI lesion burden, as well as improvement\/stabilization of disability, with a favorable safety profile.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aian.aian_165_26","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:00:19Z","timestamp":1787202019000},"page":"825-832","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year"],"prefix":"10.4103","volume":"29","author":[{"given":"MV Padma","family":"Srivastava","sequence":"first","affiliation":[{"name":"Department of Neurology, Paras Health, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Dev","family":"Mukherji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Max Super Specialty Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Rohatgi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sir Gangaram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Neurology, Artemis Hospitals, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 A review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of multiple sclerosis: Global, regional, national and sub-national-level estimates and future projections","volume":"15","author":"Khan","year":"2025","journal-title":"J Epidemiol Glob Health"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/jcm12134274","article-title":"Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges","volume":"12","author":"Khan","year":"2023","journal-title":"J Clin Med"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/pn-2024-004228","article-title":"Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance","volume":"25","author":"Rashid","year":"2025","journal-title":"Pract Neurol"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: A review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real\u2010world evaluation of ocrelizumab in multiple sclerosis: A systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.78033","article-title":"Comparative safety profiles of ocrelizumab and rituximab in multiple sclerosis treatment using real-world evidence","volume":"99","author":"Cerono","year":"2026","journal-title":"Ann Neurol"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/jcm11082081","article-title":"Prognostic markers of ocrelizumab effectiveness in multiple sclerosis: A real World Observational Multicenter Study","volume":"11","author":"Lanzillo","year":"2022","journal-title":"J Clin Med"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"123577","DOI":"10.1016\/j.jns.2025.123577","article-title":"Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis","volume":"475","author":"Kvartskhava","year":"2025","journal-title":"J Neurol Sci"},{"key":"R14-20261019","doi-asserted-by":"crossref","first-page":"e200094","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"106641","DOI":"10.1016\/j.msard.2025.106641","article-title":"Treatment outcomes in multiple sclerosis using reduced and extended interval ocrelizumab dosing","volume":"102","author":"McLean","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s13311-023-01415-y","article-title":"Effectiveness of ocrelizumab in primary progressive multiple sclerosis: A multicenter, retrospective, real-world study (OPPORTUNITY)","volume":"20","author":"Chisari","year":"2023","journal-title":"Neurotherapeutics"},{"key":"R17-20261019","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40120-023-00523-3","article-title":"Real-world clinical and economic outcomes among persons with multiple sclerosis initiating first- versus second- or later-line treatment with ocrelizumab","volume":"12","author":"Geiger","year":"2023","journal-title":"Neurol Ther"},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"105308","DOI":"10.1016\/j.msard.2023.105308","article-title":"Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"80","author":"Hauser","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R20-20261019","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/1352458516670733","article-title":"Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note","volume":"23","author":"Wang","year":"2017","journal-title":"Mult Scler"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"1149629","DOI":"10.3389\/fimmu.2023.1149629","article-title":"Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab","volume":"14","author":"Nytrova","year":"2023","journal-title":"Front Immunol"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_165_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:03:37Z","timestamp":1792415017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_165_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_165_26","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"2026-02-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}